Global Doxorubicin Market Overview

Global Doxorubicin Market size is expected to grow from USD 1.2 Billion in 2022 to USD 1.90 Billion by 2030, at a CAGR of 5.9% during the forecast period (2023–2030). 

• Doxorubicin is a chemotherapy medication used to treat a variety of cancers, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used in combination with other chemotherapy agents. Doxorubicin is a type of anthracycline, which is a class of drugs that work by interfering with the DNA of cancer cells.

• Doxorubicin is a versatile anticancer agent due to its broad spectrum of activity. Its mechanism of action involves intercalating with DNA, preventing proper replication and transcription, and inducing free radicals that damage cellular components. This approach enhances its efficacy against various cancer types. Doxorubicin is often combined with other chemotherapy agents or multidrug regimens, enhancing treatment outcomes and reducing resistance development. It has also been used with surgery, radiation therapy, and stem cell transplantation, showcasing its versatility in integrated cancer treatment plans.

• Doxorubicin, despite its therapeutic benefits, has potential side effects like cardiotoxicity, potentially limiting its cumulative dose. Healthcare professionals monitor patients during treatment and explore new formulations and delivery methods to improve drug safety. Despite these challenges, Doxorubicin remains a crucial cancer treatment tool.

Doxorubicin Market Trend Analysis:

Increasing Prevalence of Cancer

• Cancer is a global public health issue with rising incidence rates due to ageing populations, lifestyle changes, and environmental factors, necessitating a robust market for effective solutions to address the growing demand. As populations age, the risk of developing cancer increases due to age-related genetic mutations. Lifestyle factors like smoking, poor diet, and sedentary behaviours contribute to the rise in cancer cases. Industrialization and urbanization introduce environmental pollutants and carcinogens, further complicating the aetiology of cancer. This has led to increased demand for innovative diagnostics, therapies, and research initiatives to address this complex issue.

• The market is expanding due to the development of novel cancer treatments and diagnostic technologies, with biopharmaceutical companies, research institutions, and healthcare providers investing in R&D for innovative therapies, targeted treatments, and precision medicine approaches, including advanced imaging technologies and genomic profiling.

• The rising cancer prevalence has a significant economic impact on healthcare services, pharmaceuticals, medical devices, and research funding. Governments are investing in cancer research and healthcare infrastructure to address the growing burden. This growth drives advancements in oncology research, diagnostic modalities, and therapeutic interventions to meet the global demand for effective cancer management.

The Development of New Formulations of Doxorubicin

• Doxorubicin's traditional intravenous administration is linked to dose-limiting toxicities, particularly cardiotoxicity. Researchers and pharmaceutical companies are developing innovative formulations to improve drug delivery efficiency, reduce side effects, and optimize therapeutic outcomes. Liposomal formulations of Doxorubicin, a lipid-based drug, have shown promise in improving its pharmacokinetics, extending circulation time, and enhancing its accumulation within tumor tissues. This not only increases its efficacy in cancer cells but also minimizes exposure to healthy tissues, reducing systemic toxicity.

• Advancements in nanoparticle-based drug delivery systems can enhance the development of Doxorubicin formulations by selectively encapsulating and delivering the drug to tumor sites, leveraging the enhanced permeability and retention effect in cancerous tissues. This approach can increase the drug's therapeutic index while sparing healthy tissues from unnecessary exposure.

• The exploration of oral formulations of Doxorubicin is also a noteworthy avenue. While traditionally administered intravenously, the development of an oral form could significantly improve patient convenience and adherence to treatment regimens, particularly in outpatient settings. Overcoming the challenges of oral bioavailability and maintaining therapeutic efficacy presents a substantial opportunity for market growth.

Doxorubicin Market Segment Analysis:

Doxorubicin Market Segmented on the basis of Formulation, Application, and Distribution Channel

By Distribution Channel, Hospital Pharmacy segment is expected to dominate the market during the forecast period

• The Hospital Pharmacy segment dominates the pharmaceutical market due to its crucial role in patient care, medication management, and healthcare delivery. Hospitals serve as central hubs for comprehensive medical services, and their pharmacies ensure timely and effective medication administration. They focus on diverse patient needs and medical conditions, managing critical medications for surgeries, emergency care, and chronic disease management.

• Hospital pharmacy plays a crucial role in healthcare by dispensing medications, compounding them, and managing adherence. This is especially important for patients with unique needs, allergies, or specialized dosage forms. Hospital pharmacies also collaborate with healthcare providers to optimize treatment outcomes. Their role extends beyond dispensing to medication management, adherence monitoring, and collaboration with providers. This multifaceted role contributes significantly to patient safety, therapeutic efficacy, and overall healthcare quality. The hospital pharmacy segment is increasingly dominant in the market due to its critical functions in meeting diverse patient populations.

Doxorubicin Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period  

• North America dominates the global market due to its economic strength, technological advancements, and robust infrastructure. The region, dominated by major players like the US and Canada, is characterized by innovation, research, and a thriving entrepreneurial spirit. Silicon Valley, a global hub for technology, drives advancements in artificial intelligence, biotechnology, and information technology. The region's commitment to research and development is evident in its numerous world-renowned research institutions, fostering a culture of continuous innovation.

• North America's influence extends to key sectors like healthcare, finance, and manufacturing. Major pharmaceutical and biotechnology companies contribute to advancements in medicine and healthcare technologies. Government support for innovation, a well-established legal framework, and a culture that values entrepreneurship solidifies North America's dominance, attracting talent, investment, and cutting-edge technologies.

Key Players Covered in Doxorubicin Market:

• Pfizer Inc. (U.S.)

• Baxter International Inc. (U.S.)

• Johnson & Johnson Services, Inc. (U.S)

• Hikma Thymoorgan Pharmazie GmbH (Germany)

• Synbias Pharma AG (Switzerland)

• Novartis International AG (Switzerland)

• Sandoz AG (Switzerland)

• Accord Healthcare Ireland Ltd. (Ireland)

• Cadila Pharmaceuticals (India)

• Cipla Limited (India)

• SRS Pharmaceuticals Pvt. Ltd (India)

• Sun Pharmaceutical Industries Ltd. (India)

• Zydus Group ((India)

• Reddy’s Laboratories Ltd. (India)

• Glenmark Pharmaceuticals Ltd (India)

• Meiji Seika Pharma Co. Ltd. (Japan)

• MicroBiopharm Japan Co., Ltd. (Japan)

• Teva Pharmaceutical Industries Ltd. (Israel)

• Boryung Pharmaceutical Co., Ltd. (South Korea), and Other Major Players

Key Industry Developments in the Doxorubicin Market:

• In August 2021, Genentech announced positive results from the pivotal Phase III POLARIX trial investigating Polivy (polatuzumab vedotin) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus Rituxan plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The company stated that it met the primary endpoint by demonstrating significantly improved and clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL).
• In October 2021, Padagis, in partnership with Ayana Pharma Ltd, received approval from the US FDA to launch its AB-rated generic version of Doxil (Doxorubicin Liposome Injection).

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. DOXORUBICIN MARKET BY FORMULATION (2016-2030)
   1. DOXORUBICIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. LYOPHILIZED POWDER
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. DOXORUBICIN INJECTION
7. DOXORUBICIN MARKET BY APPLICATION (2016-2030)
   1. DOXORUBICIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. BLADDER CANCER
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. KAPOSI SARCOMA
   5. LEUKEMIA
   6. LYMPHOMA
   7. BREAST CANCER
   8. OTHER
8. DOXORUBICIN MARKET BY DISTRIBUTION CHANNEL (2016-2030)
   1. DOXORUBICIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITAL PHARMACY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. RETAIL PHARMACY
   5. E-COMMERCE
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. Doxorubicin Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. PFIZER INC. (U.S.)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. BAXTER INTERNATIONAL INC. (U.S.)
   4. JOHNSON & JOHNSON SERVICES, INC. (U.S)
   5. HIKMA THYMOORGAN PHARMAZIE GMBH (GERMANY)
   6. SYNBIAS PHARMA AG (SWITZERLAND)
   7. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
   8. SANDOZ AG (SWITZERLAND)
   9. ACCORD HEALTHCARE IRELAND LTD. (IRELAND)
   10. CADILA PHARMACEUTICALS (INDIA)
   11. CIPLA LIMITED (INDIA)
   12. SRS PHARMACEUTICALS PVT. LTD (INDIA)
   13. SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
   14. ZYDUS GROUP ((INDIA)
   15. REDDY’S LABORATORIES LTD. (INDIA)
   16. GLENMARK PHARMACEUTICALS LTD (INDIA)
   17. MEIJI SEIKA PHARMA CO. LTD.(JAPAN)
   18. MICROBIOPHARM JAPAN CO., LTD. (JAPAN)
   19. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
   20. BORYUNG PHARMACEUTICAL CO., LTD. (SOUTH KOREA)
10. GLOBAL DOXORUBICIN MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Formulation
       4. Historic And Forecasted Market Size By Application
       5. Historic And Forecasted Market Size By Distribution Channel
       6. Historic And Forecasted Market Size By Segment4
       7. Historic And Forecasted Market Size By Segment5
       8. Historic And Forecasted Market Size By Segment6
       9. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. DOXORUBICIN MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. DOXORUBICIN MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. DOXORUBICIN MARKET COMPETITIVE RIVALRY
TABLE 005. DOXORUBICIN MARKET THREAT OF NEW ENTRANTS
TABLE 006. DOXORUBICIN MARKET THREAT OF SUBSTITUTES
TABLE 007. DOXORUBICIN MARKET BY TYPE
TABLE 008. DOXIL MARKET OVERVIEW (2016-2028)
TABLE 009. CAELYZ MARKET OVERVIEW (2016-2028)
TABLE 010. LIPODOX MARKET OVERVIEW (2016-2028)
TABLE 011. DOXORUBICIN MARKET BY APPLICATION
TABLE 012. CLINICAL AITICANCER DRUG MARKET OVERVIEW (2016-2028)
TABLE 013. SCIENTIFIC EXPERIMENTS MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA DOXORUBICIN MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA DOXORUBICIN MARKET, BY APPLICATION (2016-2028)
TABLE 016. N DOXORUBICIN MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE DOXORUBICIN MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE DOXORUBICIN MARKET, BY APPLICATION (2016-2028)
TABLE 019. DOXORUBICIN MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC DOXORUBICIN MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC DOXORUBICIN MARKET, BY APPLICATION (2016-2028)
TABLE 022. DOXORUBICIN MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA DOXORUBICIN MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA DOXORUBICIN MARKET, BY APPLICATION (2016-2028)
TABLE 025. DOXORUBICIN MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA DOXORUBICIN MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA DOXORUBICIN MARKET, BY APPLICATION (2016-2028)
TABLE 028. DOXORUBICIN MARKET, BY COUNTRY (2016-2028)
TABLE 029. PFIZER: SNAPSHOT
TABLE 030. PFIZER: BUSINESS PERFORMANCE
TABLE 031. PFIZER: PRODUCT PORTFOLIO
TABLE 032. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. JOHNSON & JOHNSON: SNAPSHOT
TABLE 033. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 034. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 035. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. MEIJI SEIKA PHARMA: SNAPSHOT
TABLE 036. MEIJI SEIKA PHARMA: BUSINESS PERFORMANCE
TABLE 037. MEIJI SEIKA PHARMA: PRODUCT PORTFOLIO
TABLE 038. MEIJI SEIKA PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. MICROBIOPHARM JAPAN: SNAPSHOT
TABLE 039. MICROBIOPHARM JAPAN: BUSINESS PERFORMANCE
TABLE 040. MICROBIOPHARM JAPAN: PRODUCT PORTFOLIO
TABLE 041. MICROBIOPHARM JAPAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. TEVA: SNAPSHOT
TABLE 042. TEVA: BUSINESS PERFORMANCE
TABLE 043. TEVA: PRODUCT PORTFOLIO
TABLE 044. TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. BORYUNG: SNAPSHOT
TABLE 045. BORYUNG: BUSINESS PERFORMANCE
TABLE 046. BORYUNG: PRODUCT PORTFOLIO
TABLE 047. BORYUNG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. SYNBIAS PHARMA: SNAPSHOT
TABLE 048. SYNBIAS PHARMA: BUSINESS PERFORMANCE
TABLE 049. SYNBIAS PHARMA: PRODUCT PORTFOLIO
TABLE 050. SYNBIAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. STERLING: SNAPSHOT
TABLE 051. STERLING: BUSINESS PERFORMANCE
TABLE 052. STERLING: PRODUCT PORTFOLIO
TABLE 053. STERLING: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. LINGNAN PHARMACEUTICAL: SNAPSHOT
TABLE 054. LINGNAN PHARMACEUTICAL: BUSINESS PERFORMANCE
TABLE 055. LINGNAN PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 056. LINGNAN PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. SUN PHARMACEUTICAL INDUSTRIES: SNAPSHOT
TABLE 057. SUN PHARMACEUTICAL INDUSTRIES: BUSINESS PERFORMANCE
TABLE 058. SUN PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 059. SUN PHARMACEUTICAL INDUSTRIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. DOXORUBICIN MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. DOXORUBICIN MARKET OVERVIEW BY TYPE
FIGURE 012. DOXIL MARKET OVERVIEW (2016-2028)
FIGURE 013. CAELYZ MARKET OVERVIEW (2016-2028)
FIGURE 014. LIPODOX MARKET OVERVIEW (2016-2028)
FIGURE 015. DOXORUBICIN MARKET OVERVIEW BY APPLICATION
FIGURE 016. CLINICAL AITICANCER DRUG MARKET OVERVIEW (2016-2028)
FIGURE 017. SCIENTIFIC EXPERIMENTS MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA DOXORUBICIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE DOXORUBICIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC DOXORUBICIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA DOXORUBICIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA DOXORUBICIN MARKET OVERVIEW BY COUNTRY (2016-2028)